Below are 4 news articles from the past 7 days to help guide you in making your decision. Articles that are from known reputable sources have been flagged with "Trusted: True".

Article 1 of 4
Title: ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19
Publisher: Nature.com
Trusted: False
Posted: Today
The provided text appears to be a list of potential conflicts of interest for authors who contributed to a study. It details various financial and professional relationships that each author has with pharmaceutical companies, research institutions, and other organizations.
Here is the information in a more organized and concise format:
1. Affiliations: 
Some authors work at or have affiliations with:
+ Research Council of Norway
+ MRC/UKRI
+ Medical Research Council UK
+ Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool
+ Algernon Pharmaceuticals
+ Atea Pharmaceuticals
+ Regeneron Pharmaceuticals
+ Diffusion Pharmaceuticals
+ Celltrion Inc.
+ Atriva Therapeutics
2. Financial Interests: 
Authors have received:
+ Grants from various organizations (e.g., Research Council of Norway, MRC/UKRI)
+ Honoraria from pharmaceutical companies (e.g., Abbvie, Gilead Sciences, Janssen Cilag, Merck Sharp & Dohme, ViiV Healthcare)
+ Consulting fees from companies like Emergent BioSolutions and Sanofi Pasteur
+ Research grants from organizations like the Wellcome Trust and UKRI/MRC
Some authors have patents or equity in companies related to medical devices or research.
3. Other Interests: 
Authors are members of advisory boards, speaker's bureaus, or expert panels for various pharmaceutical companies (e.g., Pfizer, Roche, Gilead Sciences)
Authors participate in clinical trials and studies sponsored by pharmaceutical companies (e.g., Regeneron Pharmaceuticals, Diffusion Pharmaceuticals)
Please note that this information is based on the provided text and might not be exhaustive. It's essential to verify the accuracy of these statements with each author directly if needed.

Article 2 of 4
Title: Paxlovid Helps People With Mild COVID-19 Symptoms
Publisher: Healthline
Trusted: False
Posted: 2 days ago
Relevant.
Paxlovid reduced hospitalizations by 46 fewer admissions per 1,000 cases.
Molnupiravir may reduce hospitalizations by 16 fewer admissions per 1,000 patients.
Both antiviral drugs are effective in non-severe COVID-19 cases.
Expanding eligibility to all COVID-19 patients could benefit everyone.

Article 3 of 4
Title: Nurses union says 83% of its members report staffing shortage as fresh COVID-19 wave looms
Publisher: CBC News
Trusted: False
Posted: 3 days ago
COVID-19 hospitalizations are increasing in Saskatchewan, a neighboring province to Ontario. The article reports a 24% increase in hospitalizations over two weeks. However, the most important values mentioned are not directly related to Ontario's situation but rather to staffing shortages and healthcare system strain, which can be indirectly relevant for forecasting COVID-19 hospitalizations in Ontario.

Article 4 of 4
Title: Alberta hospitals might buckle under the next COVID wave, doctors worry
Publisher: CBC News
Trusted: False
Posted: 4 days ago
The BA.5 subvariant is driving transmission in Alberta, but similar trends have been observed in Ontario.
Positivity rates are rising throughout Alberta, with the most dramatic increase in the Calgary zone.
Hospitalizations began ticking back up in Alberta last week for the first time since early May.
Alberta's hospitalizations and emergency rooms are expected to face a "perfect storm" due to staffing shortages, burnout, patient complexity, and an unusual surge of respiratory viruses.
The article mentions Ontario as a comparison point for COVID-19 waves, indicating that forecasting models may consider trends from other provinces.